Commentary on 'Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes' by Ference BA et al., N Engl J Med 2016. 1 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a regulator of LDL-C through its ability to induce degradation of the LDL receptor (LDLR) in the lysosome of hepatocytes. In the absence of PCSK9, circulating LDLc binds to the LDLR on the surface of hepatocytes and the LDLR-LDLc complex is internalized by endocytosis. LDLc is degraded in lysosomes while the LDLR is recycled and moved back to the cell surface. In the presence of PCSK9, PCSK9 binds to the LDLR on the hepatocytes and subsequently the LDLR-PCSK9-LDLc complex occurs and is internalized. PCSK9-bound LDLR are marked for intracellular degradation and the number of LDLR on the hepatocyte is reduced. Consequently the LDLc concentration is increased.
1
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a regulator of LDL-C through its ability to induce degradation of the LDL receptor (LDLR) in the lysosome of hepatocytes. In the absence of PCSK9, circulating LDLc binds to the LDLR on the surface of hepatocytes and the LDLR-LDLc complex is internalized by endocytosis. LDLc is degraded in lysosomes while the LDLR is recycled and moved back to the cell surface. In the presence of PCSK9, PCSK9 binds to the LDLR on the hepatocytes and subsequently the LDLR-PCSK9-LDLc complex occurs and is internalized. PCSK9-bound LDLR are marked for intracellular degradation and the number of LDLR on the hepatocyte is reduced. Consequently the LDLc concentration is increased.
PCSK9-inhibiting antibodies are a 'hot topic' in cardiovascular prevention because of their potent (50%) lowering of LDL-cholesterol on top of statins. Two humanized antibodies, alirocumab and evolocumab, that bind with high affinity to PCSK9received approval by European Medicines Agency and the U.S. Food and Drug Administration, and additional PCSK9 directed therapeutics are tested in phase 1 and 2 clinical trials. PCSK9-inhibitors are being evaluated in large clinical trials that are fully recruited, however, the effects on clinical outcomes and on rare or small treatment emergent adverse effect are not fully known.
Brian Ference and colleagues addressed these questions using genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112 772 participants from 14 studies, with 14 120 cardiovascular events, and 10 635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited.
The main finding was that effects of PCSK9-and HMGCR-variants are remarkably similar: For each 10 mg/dL reduction in LDL cholesterol, PCSK9 variants were associated with an 18.9% decrease in the risk of MI or coronary death (odds ratio 0.81, 95% CI 0.74-0.89) and HMGCR variants with a 19.1% decrease (OR 0.81, 95% CI 0.72-0.90).
Statin treatment is associated with a 9% increased detection of HbA1c >6.5% that is defined as 'diabetes mellitus'. In agreement with 
